Last reviewed 09/2019

This is a serum tumour marker that is elevated in 80% of patients with advanced ovarian cancer. But this marker may also be elevated in pancreatic, gastric, colonic, and breast carcinoma; in non-malignant conditions such as benign cysts, endometriosis, pelvic inflammatory disease, and ascites; and in menstruation and pregnancy. Further, it may be normal in 50% of early stage ovarian cancer.